| Literature DB >> 22129523 |
Takanari Gotoda1, Koji Shirai, Takao Ohta, Junji Kobayashi, Shinji Yokoyama, Shinichi Oikawa, Hideaki Bujo, Shun Ishibashi, Hidenori Arai, Shizuya Yamashita, Mariko Harada-Shiba, Masaaki Eto, Toshio Hayashi, Hirohito Sone, Hiroaki Suzuki, Nobuhiro Yamada.
Abstract
Both type I and type V hyperlipoproteinemia are characterized by severe hypertriglyceridemia due to an increase in chylomicrons. Type I hyperlipoproteinemia is caused by a decisive abnormality of the lipoprotein lipase (LPL)- apolipoprotein C-II system, whereas the cause of type V hyperlipoproteinemia is more complicated and more closely related to acquired environmental factors. Since the relationship of hypertriglyceridemia with atherosclerosis is not as clear as that of hypercholesterolemia, and since type I and V hyperlipoproteinemia are relatively rare, few guidelines for their diagnosis and treatment have been established; however, type I and V hyperlipoproteinemia are clinically important as underlying disorders of acute pancreatitis, and appropriate management is necessary to prevent or treat such complications. Against such a background, here we propose guidelines primarily concerning the diagnosis and management of type I and V hyperlipoproteinemia in Japanese.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22129523 DOI: 10.5551/jat.10702
Source DB: PubMed Journal: J Atheroscler Thromb ISSN: 1340-3478 Impact factor: 4.928